7
Participants
Start Date
March 11, 2019
Primary Completion Date
February 27, 2021
Study Completion Date
February 27, 2021
CART-EGFRvIII T cells
autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.
Pembrolizumab
humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
University of Pennsylvania
OTHER